help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balleine, R. L.
Right arrow Articles by Clarke, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balleine, R. L.
Right arrow Articles by Clarke, C. L.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 4 1370-1377
Copyright © 1999 by The Endocrine Society

Original Studies

Coexpression of Alternatively Spliced Estrogen and Progesterone Receptor Transcripts in Human Breast Cancer1

Rosemary L. Balleine2, Sybille M. N. Hunt and Christine L. Clarke

Westmead Institute for Cancer Research, University of Sydney, Westmead Hospital, Westmead, New South Wales 2145, Australia

Address all correspondence and requests for reprints to: Dr. Rosemary Balleine, Westmead Institute for Cancer Research, University of Sydney, Westmead Hospital, Westmead, New South Wales 2145, Australia. E-mail: rosemary{at}hemonc.wh.su.edu.au

Primary transcripts of the human estrogen receptor (ER) and progesterone receptor (PR) are subject to a number of alternative splicing events resulting in a range of variant messenger ribonucleic acid species in receptor-positive tissues. Despite in vitro demonstrations of a possible role for some of these variants in hormonal sensitivity, the clinical significance of this process is uncertain. In this study the coexpression of variant ER and PR transcripts has been documented by RT-PCR and Southern blot analysis in a series of receptor-positive breast tumors. In 35 ER-positive tumors, a common profile of variant ER transcripts was present, with all tumors containing the {Delta}2ER and {Delta}7ER, 94% containing the {Delta}4ER, and 83% containing the {Delta}5ER. In 25 of these cases, which were also PR positive, the most highly expressed PR variants, the {Delta}4PR, {Delta}6PR, and {Delta}4/2PR, a transcript from which a 126-bp portion of PR exon 4 was deleted, were detected in over 90% of the cases. The alternatively spliced ER variants were expressed at higher relative levels than the PR species, which had mean levels of expression less than 10% that of wild-type PR. The most abundant species was the {Delta}7ER, which was present at levels ranging from 29–83% of the wild type. There was no relationship between the level of {Delta}7ER in individual tumors and the pattern of expression of the estrogen-responsive proteins PR and pS2. The common profile of alternatively spliced ER and PR transcripts in breast tumors means that this feature cannot be used as a discriminator of hormone responsiveness or other clinical end points. Further, the low level of expression of the majority of variant species calls into question their potential for impacting significantly on receptor function.




This article has been cited by other articles:


Home page
 J. Mol. Diagn.Home page
A. A. Iverson, C. Gillett, P. Cane, C. D. Santini, T. M. Vess, L. Kam-Morgan, A. Wang, M. Eisenberg, C. M. Rowland, J. J. Hessling, et al.
A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens
J. Mol. Diagn., March 1, 2009; 11(2): 117 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Schumacher, R. Guennoun, A. Ghoumari, C. Massaad, F. Robert, M. El-Etr, Y. Akwa, K. Rajkowski, and E.-E. Baulieu
Novel Perspectives for Progesterone in Hormone Replacement Therapy, with Special Reference to the Nervous System
Endocr. Rev., June 1, 2007; 28(4): 387 - 439.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Guo, H. Shen, P. Xiao, D.-H. Xiong, T.-L. Yang, Y.-F. Guo, J.-R. Long, R. R. Recker, and H.-W. Deng
Genomewide Linkage Scan for Quantitative Trait Loci Underlying Variation in Age at Menarche
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1009 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
P.B. Marshburn, J. Zhang, Z.B. Mostafavi, M.L. Matthews, J. White, and B.S. Hurst
Variant progesterone receptor mRNAs are co-expressed with the wild-type progesterone receptor mRNA in human endometrium during all phases of the menstrual cycle
Mol. Hum. Reprod., November 1, 2005; 11(11): 809 - 815.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
E Nardon, I Buda, G Stanta, E Buratti, M Fonda, and L Cattin
Insulin-like growth factor system gene expression in women with type 2 diabetes and breast cancer
J. Clin. Pathol., August 1, 2003; 56(8): 599 - 604.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society